Bibliography
- Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.
- Schulman, Ronca & Bucavalas, Inc. Allergies in America: A Landmark Survey of Nasal Allergy Sufferers. [ cited 2006 Feb 06] Executive Summary/downloadedwww.worldallergy.org.
•• Very large survey describing the impact of allergic rhinitis in patients and the difference in perception by caregivers compared with patients and parents.
- Meltzer EO, Blaiss MS, Derebery MJ, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America Survey. J Allergy Clin Immunol Sept. 2009;124(S43):S69.
•• Very large survey describing the impact of allergic rhinitis in patients and the difference in perception by caregivers compared with patients and parents.
- Meltzer EO, Gross GN, Katial R, et al.Allergic rhinitis substantially impacts patient quality of life: findings from the Nasal Allergy Survey Assessing Limitations. J FamPract. 2012;61(2):Suppl 1 S5:S10.
•• Very large survey describing the impact of allergic rhinitis in patients and the difference in perception by caregivers compared with patients and parents.
- Morales JL, Salas K, Dalvi ZXM. Qnasl® nonaqueousnaalaerosol delivers more consistent and softer sprays than aqueous Flonase®, and Nasonex®. Poster Presentation “American Academy of Allergy, Asthma & Immunology. 2013 Feb 22–26;San Antonio, TX.
- Ratner PH, Melchior A, Dunbar SA, et al.Pharmacokinetic profile of beclomethasone dipriopionate hydrofluoroalkane after intranasal administration versus oral inhalation in healthy subjects: results of a single-dose, randomized, open-label, 3-period crossover study. ClinTher. 2012;34(6):1422–1431.
- Ratner PH, Miller SD, Hampel FC, et al.Once-daily treatment with beclomethasonedipriopionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function. Ann Allergy Asthma Immunol. 2012;109:336–341.
- Berger WE, Jacobs RL, Amar NJ, et al.Efficacy and safety of beclomethasonedipropionate nasal aerosol in children with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2015;115:130–136.
- Meltzer EO, Korenblat PE, Lanier BQ, et al. Beclomethasonedipropionate nasal aerosol with an integrated dose counter: functionality and performance. Allergy Asthma Proc. 2013;34:534–541.
- Raphael GD, Berger WE, Prenner BM, et al. Efficacy, safety, and optimal dose selection of beclomethasonedipropionate nasal aerosol for seasonal allergic rhinitis in adolescents and adults. Curr Med ResOpin. 2013;29(10):1329–1340.
- Van Bavel JH, Ratner PH, Amar NJ, et al.Efficacy and safety of once-daily treatment with beclomethasonedipropionate nasal aerosol in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2012;33(5):386–396.
- Meltzer EO, Jacobs RL, LaForce CF, et al.BDP HFA nasal aerosol 320 µg once daily is safe and effective in the treatment of nasal symptoms associated with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2011;107(11):A118.
- Meltzer EO, Jacobs RL, LaForce CF, et al.Safety and efficacy of one-daily treatment with beclomethasonedipropionate nasal aerosol in subjects with perennial allergic rhinitis. Allergy Asthma Proc. 2012;33:249–257.
- Weinstein SF, Andrews CP, Shah SR, et al. Long-term efficacy and safety of once-daily treatment with beclomethasonedipropionate nasal aerosol. Allergy Asthma Proc. 2014;35(4):323–331.
- Storms WW, Segall N, Mansfield LE, et al. Efficacy and safety of beclomethasonedipropionate nasal aerosol in pediatric patients with seasonal allergic rhinitis. Ann Allergy Asthma Immunol. 2013;111(5):408–414
- Berger WE, Jacobs RL, Amar NJ, et al.Efficacy and safety of beclomethasone dipropionate nasal aerosol in children (4-11 years of age) with perennial allergic rhinitis. Poster Presentation Annual Meeting The American College of Allergy, Asthma and Immunology 2014 Nov 6–10;Atlanta, GA.
- Tran NP, Vickery J, Blaiss MS. Management of rhinitis: allergic and non-allergic. Allergy Asthma Immunol Res. 2011;3(3):148–156.
- Almazan-Aguilar NA. Intranasal corticosteroids for the medical management of nasal polyps in adults: a meta-analysis. Philipp J Otolaryngol Head Neck Surg. 2007;22(1,2):5–11.
- Lee LA, Sterling R, Maspero J, et al.Growth velocity reduced with once-daily fluticasone furoate nasal spray in prepubescent children with perennial allergic rhinitis. J Allergy ClinImmunolPract. 2014;2(4):421–427.
• Once daily in the morning triamcinolone demonstrated minimal negative effects on growth.
- Hampel FC, Nayak NA, Segall N, et al. Once-daily treatment with beclomethasone dipropionate nasal aerosol (80 µg) does not affect hypothalamic-pituitary-adrenal axis function in children with perennial allergic rhinitis. Poster Presentation American College of Allergy, Asthma and Immunology; 2013 Nov 7–11; Baltimore, MD.
- Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasonedipropionate. Pediatrics. 2000;105(2):E23.
- Skoner DP, Berger WE, Gawchik SM, et al.Intranasal triamcinolone and growth velocity. Pediatrics. 2015;135(2):e348–56.
- Schendel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105(2):E22.
•• Once daily in the morning intranasal mometasone did not cause statistically significant growth retardation.
- Gross GN, Settipane RA, Ford LB, et al.Patient satisfaction with beclomethasonedipropionate nasal aerosol device with integrated dose counter during daily use. Allergy Asthma Proc. 2013;34(6):527–533.
- Leach CL, Kuehl PJ, Chand R, et al.Nasaldeposition of HFA-beclometasone, aqueous flutacasone propionate and aqueous mometasone furoate in allergic rhinitis patients. Jour of Aerosol Med and Pulmon Drug Delivery. 2015;28:1–9.